ImmuCell says strong cash position prompts end to at-the-market offering
ICCC•ImmuCell reported third-quarter 2026 net income of $953,000, compared with a $140,000 loss a year earlier, as revenue rose 46% to $8.04 million. The company terminated its at-the-market offering, citing its strong cash position, and expects to sign a newly negotiated $3 million bank line of credit in the fourth quarter.
1. Quarterly results
ImmuCell reported third-quarter 2026 net income of $953,000, compared with a $140,000 loss a year earlier, while revenue increased 46% to $8.04 million. The increase partly reflected the absence of distributor restocking headwinds that had hurt sales a year earlier. Gross margin rose to 44.2% from 42.9%, reflecting higher pricing and manufacturing execution.
2. Financing plans
Management terminated the at-the-market offering, citing a strong cash position. A newly negotiated $3 million bank line of credit is expected to be signed in the fourth quarter.




